Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10 | ― | 10.30% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $125 | ― | 7.30% | Reiterated | ||||
 | Genpact | BUY $56 | ― | -0.10% | Reiterated | Analysts Offer Insights on Technology Companies: Genpact (NYSE: G) and Lyft (NASDAQ: LYFT) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $95 | ― | 5.30% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $22→$30 | ― | 14.10% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $33→$34 | ― | 7.40% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $246→$320 | ― | 13.10% | Reiterated | ||||
| Sila Realty Trust, Inc. | HOLD $27 | ― | -2.20% | Initiated | Sila Realty Trust initiated with an Equal Weight at Wells Fargo | |||
| SharkNinja, Inc. | BUY $140 | ― | -0.30% | Reiterated | SharkNinja, Inc.: Strong Growth Potential Driven by Innovation, Strategic Expansion, and Direct Retail Relationships | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $27 | ― | 16.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $8.5 | ― | 5.70% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY | ― | 24.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $130→$143 | ― | 5.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $84→$91 | ― | 1.50% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $16→$21 | ― | 6.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $128→$165 | ― | 10.50% | Upgraded | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $18.75→$30.5 | ― | 43.90% | Reiterated | ||||
| Oklo Inc | HOLD | ― | -9.60% | Downgraded | Oklo downgraded to Neutral from Buy at Seaport Research | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $34→$38 | ― | 13.00% | Reiterated | ||||
| Kenvue, Inc. | HOLD $23→$18 | ― | 0.60% | Reiterated | Kenvue, Inc.: Hold Rating Amid FDA Concerns and Balanced Risks | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $23 | ― | 6.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $20 | ― | 14.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $30 | ― | 10.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $20→$23 | ― | 2.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $180→$215 | ― | 50.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $185 | ― | 0.50% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $87 | ― | 7.60% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY | ― | 7.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY | ― | 7.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $259→$228 | ― | 5.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $200 | ― | 12.10% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $60→$59 | ― | 13.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $5→$10 | ― | 10.40% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $55 | ― | 34.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $40 | ― | 20.30% | Reiterated | ||||
| Crispr Therapeutics AG | BUY $80 | ― | -7.90% | Reiterated | Crispr Therapeutics AG: Buy Rating Backed by Promising Developments and Market Opportunities | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $18 | ― | 20.30% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $25 | ― | 16.20% | Reiterated | ||||
| Prelude Therapeutics | BUY $5 | ― | -11.50% | Reiterated | Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating | |||
| Caribou Biosciences | BUY $3 | ― | -11.50% | Reiterated | Caribou Biosciences: Promising HLA Data and Trial Results Reinforce Buy Rating | |||
 | OKYO Pharma Limited Sponsored ADR | BUY $7 | ― | -2.20% | Reiterated | Analysts Offer Insights on Healthcare Companies: Mind Medicine (NASDAQ: MNMD) and OKYO Pharma Limited Sponsored ADR (NASDAQ: OKYO) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $4.5 | ― | 5.60% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $45→$40 | ― | 15.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $45→$40 | ― | 15.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $27.5→$30 | ― | 43.90% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $10→$15 | ― | 15.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $35→$55 | ― | 15.20% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $274 | ― | 6.10% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $1,070 | ― | 18.30% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $120→$152 | ― | 29.10% | Reiterated |
Rows:
